SCHEMBL5483219

SCHEMBL5483219

O=c1[nH]nc2cc(-c3c(O)cccc3CN3CCN(c4ccccn4)CC3)c3ccccc3n12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.47
MAPT P10636 4/20 0.44
MAPK1 P28482 4/20 0.44
KMT2A Q03164 3/20 0.44
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 1/20 0.44
USP2 O75604 1/20 0.44
RAB9A P51151 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
NOD2 Q9HC29 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 4/20 0.44
PARP1 P09874 3/20 0.41
CHIA Q9BZP6 1/20 0.41
HTR7 P34969 1/20 0.40
CHEK1 O14757 3/20 0.40
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5476213 0.88 HTR1A (0.48) MAPTMAPK1KMT2ALMNASMN1; SMN2
SCHEMBL5472646 0.86 CHEK1 (0.50) KDM4EALDH1A1CHEK1CYP3A4CYP2D6
SCHEMBL5478030 0.82 CHEK1 (0.48) DRD2MAPTKMT2ALMNASMN1; SMN2
SCHEMBL5465346 0.80 LMNA (0.49) DRD2MAPTMAPK1KMT2ALMNA
SCHEMBL5474870 0.78 CHEK1 (0.39) MAPTSMN1; SMN2KDM4ENPSR1ALDH1A1
SCHEMBL5469353 0.76 CHEK1 (0.40) LMNAKDM4EPARP1CHEK1
SCHEMBL5480704 0.74 CHEK1 (0.49) DRD2HTR7CHEK1DRD4DRD3
SCHEMBL5476236 0.72 CHEK1 (0.54) RAB9ACHEK1
SCHEMBL5469930 0.67 CHEK1 (0.52) DRD2MAPTKDM4EALDH1A1HTR7
SCHEMBL12822001 0.67 ALDH1A1 (0.56) DRD2MAPTMAPK1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070149560-A1 Novel fused triazolones and the uses thereof ASTRAZENECA AB (SE) 2007-06-28 US claimed
JP-2006520397-A 2006-09-07 JP claimed
EP-1613625-A1 NOVEL FUSED TRIAZOLONES AND THE USES THEREOF AstraZeneca AB (SE) 2006-01-11 EP claimed
WO-2004081008-A1 NOVEL FUSED TRIAZOLONES AND THE USES THEREOF ASTRAZENECA AB (SE) 2004-09-23 WO claimed
US-20070149560-A1 Novel fused triazolones and the uses thereof ASTRAZENECA AB (SE) 2007-06-28 US disclosed
EP-1613625-A1 NOVEL FUSED TRIAZOLONES AND THE USES THEREOF AstraZeneca AB (SE) 2006-01-11 EP disclosed
WO-2004081008-A1 NOVEL FUSED TRIAZOLONES AND THE USES THEREOF ASTRAZENECA AB (SE) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149560-A1 Novel fused triazolones and the uses thereof TP53, BRCA1, KLK3 DRD2 4307/4885MAPT 2300/4885MAPK1 3935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.